Axsome Therapeutics (NASDAQ:AXSM) Stock Rating Reaffirmed by BTIG Research

Share on StockTwits

Axsome Therapeutics (NASDAQ:AXSM)‘s stock had its “positive” rating restated by investment analysts at BTIG Research in a note issued to investors on Wednesday, The Fly reports. They presently have a $48.00 price target on the stock. BTIG Research’s target price suggests a potential upside of 8.50% from the company’s current price.

A number of other research firms also recently issued reports on AXSM. Cantor Fitzgerald lifted their target price on Axsome Therapeutics from $45.00 to $55.00 and gave the company an “overweight” rating in a research report on Tuesday. Guggenheim assumed coverage on Axsome Therapeutics in a research report on Wednesday, October 16th. They set a “buy” rating and a $48.00 price target for the company. HC Wainwright restated a “buy” rating and issued a $30.00 price target on shares of Axsome Therapeutics in a research note on Thursday, October 17th. ValuEngine downgraded Axsome Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday. Finally, William Blair started coverage on Axsome Therapeutics in a research report on Wednesday, September 18th. They set an “outperform” rating and a $48.00 price target on the stock. Two analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Axsome Therapeutics currently has an average rating of “Buy” and an average price target of $42.67.

Shares of AXSM stock opened at $44.24 on Wednesday. The firm’s fifty day moving average price is $28.30 and its two-hundred day moving average price is $25.34. The company has a current ratio of 2.39, a quick ratio of 2.39 and a debt-to-equity ratio of 2.80. Axsome Therapeutics has a 1 year low of $1.94 and a 1 year high of $47.68. The firm has a market capitalization of $1.36 billion, a P/E ratio of -38.47 and a beta of 2.84.

Axsome Therapeutics (NASDAQ:AXSM) last posted its quarterly earnings data on Thursday, November 7th. The company reported ($0.56) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.41) by ($0.15). As a group, equities research analysts forecast that Axsome Therapeutics will post -1.7 EPS for the current fiscal year.

In other news, CFO Nick Pizzie acquired 2,180 shares of the stock in a transaction dated Thursday, September 26th. The shares were bought at an average cost of $24.80 per share, for a total transaction of $54,064.00. Following the purchase, the chief financial officer now directly owns 40,440 shares of the company’s stock, valued at $1,002,912. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 27.50% of the stock is owned by insiders.

A number of large investors have recently modified their holdings of the stock. Metropolitan Life Insurance Co NY bought a new position in Axsome Therapeutics during the third quarter worth about $171,000. Point72 Asset Management L.P. acquired a new position in shares of Axsome Therapeutics in the 3rd quarter valued at $3,238,000. California State Teachers Retirement System boosted its position in shares of Axsome Therapeutics by 4.6% in the 3rd quarter. California State Teachers Retirement System now owns 39,214 shares of the company’s stock valued at $794,000 after purchasing an additional 1,722 shares during the period. State Street Corp increased its stake in Axsome Therapeutics by 12.0% in the 3rd quarter. State Street Corp now owns 729,682 shares of the company’s stock worth $14,769,000 after purchasing an additional 78,209 shares in the last quarter. Finally, California Public Employees Retirement System increased its stake in Axsome Therapeutics by 15.7% in the 3rd quarter. California Public Employees Retirement System now owns 27,134 shares of the company’s stock worth $549,000 after purchasing an additional 3,692 shares in the last quarter. Institutional investors and hedge funds own 54.64% of the company’s stock.

About Axsome Therapeutics

Axsome Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing novel therapies for central nervous system (CNS) disorders in the United States. Its product pipeline includes AXS-05, which is in the Phase III clinical trial for the treatment resistant depression; Phase II/III clinical trials in agitation associated with Alzheimer's disease; and Phase II clinical trial for the treatment of smoking cessation, as well as for major depressive disorder.

Read More: How Do You Make Money With Penny Stocks?

The Fly

Analyst Recommendations for Axsome Therapeutics (NASDAQ:AXSM)

Receive News & Ratings for Axsome Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.